Alkeon Capital Management LLC Acquires 220,000 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Alkeon Capital Management LLC lifted its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 34.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 853,845 shares of the biotechnology company's stock after purchasing an additional 220,000 shares during the quarter. Alkeon Capital Management LLC owned 0.89% of Sarepta Therapeutics worth $103,819,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the business. Manchester Capital Management LLC lifted its position in Sarepta Therapeutics by 86.6% during the 4th quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company's stock worth $29,000 after buying an additional 110 shares in the last quarter. MassMutual Private Wealth & Trust FSB raised its holdings in Sarepta Therapeutics by 169.6% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company's stock worth $30,000 after acquiring an additional 156 shares in the last quarter. Newbridge Financial Services Group Inc. acquired a new position in Sarepta Therapeutics during the fourth quarter valued at approximately $36,000. Steward Partners Investment Advisory LLC grew its stake in Sarepta Therapeutics by 164.4% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company's stock valued at $38,000 after purchasing an additional 194 shares in the last quarter. Finally, Smartleaf Asset Management LLC increased its position in shares of Sarepta Therapeutics by 95.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 442 shares of the biotechnology company's stock worth $54,000 after purchasing an additional 216 shares during the last quarter. Institutional investors and hedge funds own 86.68% of the company's stock.

Sarepta Therapeutics Price Performance

Sarepta Therapeutics stock opened at $63.51 on Friday. The firm has a market cap of $6.24 billion, a PE ratio of 50.81 and a beta of 0.93. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. The stock's fifty day moving average price is $72.86 and its two-hundred day moving average price is $103.71. Sarepta Therapeutics, Inc. has a one year low of $48.01 and a one year high of $173.25.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. Cantor Fitzgerald reissued an "overweight" rating and issued a $163.00 price objective on shares of Sarepta Therapeutics in a report on Tuesday, March 18th. HC Wainwright reissued a "neutral" rating and issued a $75.00 price objective on shares of Sarepta Therapeutics in a research report on Wednesday, April 16th. Wells Fargo & Company assumed coverage on shares of Sarepta Therapeutics in a report on Friday, April 11th. They issued an "overweight" rating and a $115.00 target price on the stock. Needham & Company LLC reduced their price target on Sarepta Therapeutics from $202.00 to $183.00 and set a "buy" rating for the company in a report on Thursday, April 3rd. Finally, Royal Bank of Canada lowered Sarepta Therapeutics from an "outperform" rating to a "sector perform" rating and dropped their price objective for the company from $161.00 to $87.00 in a research note on Monday, March 31st. Six equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, Sarepta Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $158.70.

Insider Transactions at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of the firm's stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total value of $248,203.24. Following the transaction, the director now directly owns 27,812 shares of the company's stock, valued at $2,771,187.68. This trade represents a 8.22 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 7.70% of the stock is currently owned by insiders.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.